INmuneBIO
INmune Bio is a clinical-stage biotechnology company developing innate immune system immunotherapies for Alzheimer's disease, rare diseases like RDEB, and cancer. Pre-revenue, with multiple platforms advancing toward FDA and MHRA regulatory submissions targeted for 2026-2027.
- Company typePublic
- Founded2015
- HeadquartersLa Jolla, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What INmuneBIO does
INmune Bio Inc. is a clinical-stage biotechnology company developing immunotherapies that reprogram the patient's innate immune system to fight cancer, neurodegenerative disease, and rare inflammatory conditions. The company operates four core platforms: the DN-TNF platform with lead asset XPro1595 (pegipanermin), a dominant-negative tumor necrosis factor inhibitor that selectively neutralizes soluble TNF to reduce neuroinflammation without compromising protective immune function; the CORDStrom MSC platform delivering pooled, allogeneic, umbilical cord-derived mesenchymal stromal cells, with lead indication Ebstrocel for Recessive Dystrophic Epidermolysis Bullosa (RDEB); the INKmune NK cell priming platform for hematologic malignancies; and INB03, a soluble TNF inhibitor targeting myeloid-derived suppressor cells in solid tumors. The company has received FDA Fast Track designation for XPro1595 and Orphan Drug plus Rare Pediatric Disease designations for CORDStrom, with FDA End-of-Phase 2 alignment secured for an integrated Phase 2b/3 registration pathway.
INmune Bio serves three primary patient segments: approximately 300 RDEB children in the UK (5,000+ in the broader EB community), early Alzheimer's disease patients with inflammatory biomarkers (a market projected to grow from $4 billion in 2025 to $40 billion by 2036 in the 7MM), and oncology patients with HER2+ breast cancer and other immunotherapy-resistant solid tumors. Phase 2 MINDFuL trial data for XPro1595 demonstrated statistically significant treatment effect on myelin (p=0.0028 full population; p=0.0098 biomarker-enriched) with no observed ARIA-E or ARIA-H brain imaging abnormalities, while MissionEB Phase III data for CORDStrom showed 26% itch reduction at six months with significant pain, skin, and quality-of-life improvements.
INmune Bio is pre-revenue with no approved products and no commercial sales. The future business model contemplates revenue from approved biopharmaceutical products distributed through specialty pharmacy channels and hospital/academic medical center dispensaries typical for rare disease and neurology biologics. The company held $24.8 million in cash as of December 31, 2025, providing runway through Q1 2027, with cumulative capital raised since the 2019 IPO exceeding $130 million across public offerings, registered direct offerings, an ATM facility, and a $15 million Silicon Valley Bank credit facility. Key manufacturing and supply partnerships include CGT Catapult for commercial-scale CORDStrom production and Anthony Nolan for umbilical cord tissue procurement.
INmuneBIO firmographics
Firmographics- Name
- INmuneBIO
- Legal name
- INmune Bio Inc.
- Website
- https://inmunebio.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- INmune Bio is a clinical-stage biotechnology company developing innate immune system immunotherapies for Alzheimer's disease, rare diseases like RDEB, and cancer. Pre-revenue, with multiple platforms advancing toward FDA and MHRA regulatory submissions targeted for 2026-2027.
- Ownership category
- akta.pro rank
INmuneBIO industry classification
Industry- Product category
- Clinical-Stage Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)
- akta.pro secondary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where INmuneBIO is headquartered
LocationHeadquarters
- HQ city
- La Jolla
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
INmuneBIO business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Biopharmaceutical Product Revenue: Pre-revenue clinical-stage biotechnology company. Expected future revenue from sale of approved biopharmaceutical products including CORDStrom for RDEB and XPro1595 for Alzheimer's disease. No products currently approved or generating revenue.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
INmuneBIO product offering
Product offeringCore offering
INmune Bio is a clinical-stage biotechnology company developing first-in-class immunotherapies that reprogram the innate immune system to fight disease. The company's pipeline is anchored by two lead programs: CORDStrom (Ebstrocel), a pooled allogeneic human umbilical cord-derived mesenchymal stromal cell (hucMSC) platform targeting Recessive Dystrophic Epidermolysis Bullosa (RDEB), and XPro1595 (pegipanermin), a dominant-negative TNF (DN-TNF) inhibitor for early Alzheimer's disease. Additional programs include INKmune (NK cell priming pseudokine) and INB03 (soluble TNF inhibitor) for oncology indications.
Product overview
INmune Bio Inc. is a clinical-stage biotechnology company developing immunotherapies that reprogram a patient's innate immune system to fight cancer and Alzheimer's disease. The company operates two main product platforms: the DN-TNF (Dominant-Negical TNF) platform comprising XPro1595 (pegipanermin), INB03, Quellor, and LIVNate, which selectively neutralizes soluble TNF to treat inflammation-driven diseases; and the Natural Killer Cell Priming Platform featuring INKmune for cancer treatment. Additionally, the CORDStrom mesenchymal stromal cell platform is advancing toward regulatory filings for Recessive Dystrophic Epidermolysis Bullosa (RDEB). The company utilizes a precision medicine approach, matching drug mechanisms to patient biology.
Differentiator
Problem solved
Functional benefit
Brands
- CORDStrom: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell (hucMSC) platform for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB) and other inflammatory diseases. Ebstrocel is the RDEB-specific formulation derived from this platform.
- XPro
- INKmune
- INB03
Products and services
- XPro1595 (pegipanermin) A next-generation Dominant-Negative Tumor Necrosis Factor (DN-TNF) biologic that selectively neutralizes soluble TNF (sTNF) to eliminate neuroinflammation without compromising protective immune function. In Phase 2b/3 registrational development for early Alzheimer's disease with biomarkers of inflammation.
- CORDStrom (Ebstrocel) A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell (hucMSC) platform engineered to address donor variability and manufacturing inconsistency. Lead indication is RDEB, a rare genetic skin disorder causing severe wounds, intractable itch, and chronic pain.
- INKmune A natural killer (NK) cell priming platform delivered as a pharmaceutical-grade, replication-incompetent tumor cell that primes patients' resting NK cells to eliminate minimal residual disease in cancer patients, including high-risk MDS and ovarian cancer.
- INB03 A soluble TNF inhibitor targeting myeloid-derived suppressor cells (MDSC) to overcome resistance to immunotherapy such as anti-PD1 checkpoint inhibitors. In development for MUC4-expressing cancers and HER2-positive breast cancer.
Quantifiable outcome
- 26% itch reduction at 6 months in RDEB patients treated with CORDStrom
- +4 more outcomes
Companies that use INmuneBIO
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
INmuneBIO technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
INmuneBIO partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- American Biotech Innovation Alliance (ABIA)minorINmune Bio became a founding member of ABIA, a coalition of 21-26 biotech companies developing a national innovation roadmap to sustain U.S. leadership in biotechnology. The alliance addresses declining public investment, capital market volatility, regulatory complexity, and global competition through Vision 2030 strategy focusing on manufacturing capacity, research investment, regulatory flexibility, and workforce development.
- Anthony NolancoreExpanded collaboration with Anthony Nolan, a UK-based stem cell charity with 50 years of expertise, to secure umbilical cord tissue for CORDStrom MSC platform development. The restated agreement secures long-term provision of umbilical cord tissue from Anthony Nolan's procurement infrastructure to support development of off-the-shelf cellular treatments for RDEB, oncology applications, and inflammatory diseases (osteoarthritis, systemic lupus erythematosus).
- CGT CatapultcorePartnership with Cell and Gene Therapy Catapult (CGT Catapult) for commercial manufacturing of CORDStrom. Three commercial pilot-scale manufacturing runs completed at the CGT Catapult facility in the UK, each meeting predefined release criteria and confirming commercial supply readiness.
- Xencor, Inc.minor$15 million credit facility with Silicon Valley Bank to fund buyout of option held by Xencor, Inc. Transaction included $15 million cash payment and $3.3 million in shares to Xencor, preventing approximately 2.1 million shares of potential future stock dilution.
- DEBRA UKminorMentioned as supporting organization for epidermolysis bullosa patient community. Approximately 300 children in UK affected by RDEB, part of broader EB community of at least 5,000 individuals.
Scale indicators12 records
Recent moves7 records
Expansion highlights6 records
INmuneBIO competitors and assessment
Company assessmentEmerging players
- Cortexyme: Cortexyme is a clinical-stage biotech developing therapeutics targeting microbial pathogens in neurodegenerative disease, including Alzheimer's. Comparable as a small-cap clinical-stage neuroscience biotech pursuing novel mechanisms, though with a different therapeutic hypothesis.
- Pluristem Therapeutics: Pluristem Therapeutics is a clinical-stage regenerative medicine company developing placenta-derived allogeneic cell therapies for inflammatory and ischemic conditions. Comparable as a small-cap allogeneic cell therapy peer, though using a different cell source (placenta vs. umbilical cord) and earlier-stage pipeline.
- ProKidney: ProKidney is a clinical-stage cell therapy company developing autologous cell therapies for chronic kidney disease. Comparable to INmune Bio as another clinical-stage biotech using cell-based approaches for serious diseases with limited treatment options, though focused on renal rather than dermatologic or neurologic indications.
Direct peers
- Nkarta: Nkarta is a clinical-stage biotech engineering allogeneic NK cell therapies for cancer, including hematologic malignancies. Closely comparable to INKmune for NK cell-based oncology approaches, though Nkarta uses gene-engineered NK cells rather than in vivo priming.
- Annovis Bio: Annovis Bio is a clinical-stage biotech developing neurodegenerative disease therapeutics targeting toxic protein aggregates and inflammation. Comparable as a small-cap biotech advancing novel mechanisms for Alzheimer's and Parkinson's, with overlapping biomarker-driven patient enrichment approaches.
- Fate Therapeutics: Fate Therapeutics is a clinical-stage biotech developing off-the-shelf NK cell and T-cell cancer immunotherapies. Directly comparable to INmune Bio's INKmune NK cell priming platform in oncology, with similar iPSC-derived and engineered NK cell approaches for hematologic malignancies and solid tumors.
- Mesoblast: Mesoblast is a commercial-stage cell therapy company developing allogeneic mesenchymal lineage cell therapies for inflammatory and rare diseases. Highly comparable to INmune Bio's CORDStrom MSC platform, with similar manufacturing, regulatory, and commercialization dynamics in specialty biologics.
- Cassava Sciences: Cassava Sciences is a clinical-stage biotechnology company developing treatments for Alzheimer's disease, with a late-stage asset in pivotal trials. Directly comparable to INmune Bio's XPro1595 program as another small-cap, clinical-stage Alzheimer's biotech pursuing a differentiated mechanism.
- Alector: Alector is a clinical-stage biotech developing immuno-neurology treatments for neurodegenerative diseases, including Alzheimer's, with a focus on neuroinflammation biology. Highly comparable to INmune Bio's XPro1595 program, and notably was a lead investor in INmune Bio's early financing, validating overlapping scientific conviction.
- Lineage Cell Therapeutics: Lineage Cell Therapeutics is a clinical-stage cell therapy company developing allogeneic cell transplant therapies for CNS disorders, oncology, and rare diseases. Comparable to CORDStrom as another small-cap allogeneic cell therapy biotech pursuing regulatory approvals in underserved indications.
Market position
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
INmuneBIO social profiles
Digital presenceINmuneBIO compliance and trust
Trust signalCompliance3 records
INmuneBIO financial estimates
Financial estimateRevenue estimate
Valuation estimate
INmuneBIO leadership team
Management profileNumber of profiles
Profiles10 records
INmuneBIO funding detail
Funding detailFunding overview
Funding rounds10 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
INmuneBIO M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about INmuneBIO
What does INmuneBIO do?
INmune Bio is a clinical-stage biotechnology company developing first-in-class immunotherapies that reprogram the innate immune system to fight disease. The company's pipeline is anchored by two lead programs: CORDStrom (Ebstrocel), a pooled allogeneic human umbilical cord-derived mesenchymal stromal cell (hucMSC) platform targeting Recessive Dystrophic Epidermolysis Bullosa (RDEB), and XPro1595 (pegipanermin), a dominant-negative TNF (DN-TNF) inhibitor for early Alzheimer's disease. Additional programs include INKmune (NK cell priming pseudokine) and INB03 (soluble TNF inhibitor) for oncology indications.
Is INmuneBIO a public or private company?
INmuneBIO is a public company. It is classified as public and is currently operating.
When was INmuneBIO founded?
INmuneBIO was founded in 2015. It employs 11 to 50 people.
Where is INmuneBIO based?
INmuneBIO is headquartered in La Jolla, United States, in the North America region.
How does INmuneBIO make money?
One revenue line is on record: biopharmaceutical Product Revenue.
Who are INmuneBIO's main competitors?
Emerging players on record are Cortexyme, Pluristem Therapeutics and ProKidney. Direct peers are Nkarta, Annovis Bio, Fate Therapeutics, Mesoblast, Cassava Sciences, Alector and Lineage Cell Therapeutics.
Does INmuneBIO have an API?
No public API is recorded for INmuneBIO.
What industry is INmuneBIO in?
INmuneBIO's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.